TLX-054

TLX-054 is an injectable drug candidate currently under development through a strategic partnership between Easywell Biomedical and Formosa Laboratories (also known as Taiwan Chia Tai). Announced in November 2025, the development program leverages Formosa Laboratories' expertise in active pharmaceutical ingredient (API) manufacturing and injectable production alongside Tulex Pharmaceuticals' (a subsidiary of Easywell Biomedical) experience in formulation and international regulatory navigation. The drug is positioned as a high-value, complex medicine, with a specific focus on long-acting injectable technology. While the specific therapeutic indication and biological target have not been publicly disclosed, the project is part of a broader effort to expand into high-technical-barrier pharmaceutical markets, likely utilizing the 505(b)(2) regulatory pathway.